Dr. Reddy's Laboratories - Strong Growth Across Business Segments
We reiterate our Buy rating on Dr. Reddy’s Laboratories (DRL) with a target price (TP) of Rs5,424. 4QFY22 earnings performance was above expectations
358 Views
Dr Reddys Labs: Stable Results Despite Industry Headwinds; Maintain BUY
The company is building a global pipeline of biosimilars, developments of NCE for Immuno-oncology, and building up a Neutraceuticals portfolio,...
496 Views
HSIE Results Daily: DLF, Dr. Reddy’s, IndusInd Bank and More
HSIE Results Daily DLF: DLF surprised positively on presales at INR 10bn (6.6x/-5% YoY/QoQ) despite the lockdown during the quarter. While office...
210 Views
India drives earnings growth, while North America/PSAI drags it down
Dr. Reddy's Labs (DRRD) delivered a miss on earnings in 1QFY22, affected by a) higher price erosion in North America (NAM) sales, b) the deferment...
233 Views
Dr Reddys Labs: Operational Excellence and Continuous Improvement
DRRD delivered a strong performance led by the volume growth and new product launches across these markets. We expect revenue and PAT CAGR of 10.3%...
226 Views